Modeling the natural history of ductal carcinoma in situ based on population data

Sarocha Chootipongchaivat 1*, Nicolien T. van Ravesteyn 1, Xiaoxue Li 2,3, Hui Huang 2, Harald Weedon-Fekjaer 4, Marc D. Ryser 5,6, Donald L. Weaver 7, Elizabeth S. Burnside 8, Brandy M. Heckman-Stoddard 9, Harry J. de Koning 1 and Sandra J. Lee 2,3

Abstract

Background: The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision.

Methods: Two well-established population models evaluated six possible DCIS natural history submodels. The submodels assumed 30%, 50%, or 80% of breast lesions progress from undetectable DCIS to preclinical screen-detectable DCIS; each model additionally allowed or prohibited DCIS regression. Preclinical screen-detectable DCIS could also progress to clinical DCIS or invasive breast cancer (IBC). Applying US population screening dissemination patterns, the models projected age-specific DCIS and IBC incidence that were compared to Surveillance, Epidemiology, and End Results data. Models estimated mean sojourn time (MST) in the preclinical screen-detectable DCIS state, overdiagnosis, and the risk of progression from preclinical screen-detectable DCIS.

Results: Without biopsy and surgical excision, the majority of DCIS (64–100%) in the preclinical screen-detectable state progressed to IBC in submodels assuming no DCIS regression (36–100% in submodels allowing for DCIS regression). DCIS overdiagnosis differed substantially between models and submodels, 3.1–65.8%. IBC overdiagnosis ranged 1.3–2.4%. Submodels assuming DCIS regression resulted in a higher DCIS overdiagnosis than submodels without DCIS regression. MST for progressive DCIS varied between 0.2 and 2.5 years.

Conclusions: Our findings suggest that the majority of screen-detectable but unbiopsied preclinical DCIS lesions progress to IBC and that the MST is relatively short. Nevertheless, due to the heterogeneity of DCIS, more research is needed to understand the progression of DCIS by grades and molecular subtypes.

Keywords: United States, Breast neoplasms, Early detection of cancer, Disease progression, Breast carcinoma in situ
is not life-threatening, it can progress to invasive breast cancer (IBC) if left untreated [3, 4]. The most common treatment options for DCIS are breast-conserving surgery, usually with breast irradiation, and total mastectomy [5]. Although the detection of DCIS has increased substantially relative to detection of invasive breast cancer, its natural history remains poorly understood. In particular, there is considerable uncertainty about the rates of DCIS progression and regression.

To date, two approaches have been used to characterize DCIS natural history. In the first approach, observational studies have focused on women with a biopsy-confirmed diagnosis of DCIS who did not undergo definitive surgery [3, 4, 6–12]. However, because such observational studies report on outcomes in patients who received core needle or excisional biopsies, the findings do not directly ascertain the unobserved natural history of progression. To address this caveat, a second approach uses mathematical models in conjunction with clinical data and/or data from mammography screening studies to infer latent disease dynamics [13–16].

Estimates of progression risk and mean sojourn time (MST), that is, the time from preclinical DCIS to IBC, vary widely between the two approaches and even between studies of the same approach. For instance, progression risk estimates are generally lower for biopsy-treated women in observational studies (ranging from 12 to 52% [4, 6–12]) than from modeling studies (ranging from 61 to 91% [13, 14, 17, 18]).

Due to the residual uncertainty about natural history, the extent of breast cancer overdiagnosis and overtreatment are difficult to quantify. Indeed, while researchers generally accept that a fraction of screen-detected DCIS and IBC lesions would not progress to clinical disease if left untreated [10], estimates of overdiagnosis range from less than 1% [19] to 37% [13]. Currently ongoing active monitoring trials for low-risk DCIS patients [20–22] are expected to provide an estimate of the risk of progression from biopsy-confirmed DCIS to invasive disease. However, these trials rely on statistical inference rather than direct observation to provide insight into unobservable natural history dynamics.

Here we developed an alternative modeling approach to study DCIS natural history. Rather than relying on data from screening studies, we employed population-based models of incidence and progression in conjunction with breast cancer incidence data from the Surveillance, Epidemiology and End Results (SEER) program. By comparing two independently developed and validated population models of breast cancer, and evaluating multiple submodels for each, we explored a range of possible natural histories and projected the resulting extent of overdiagnosis.

**Materials and methods**

**Model description**

Two well-established models have been used for this study, which were developed in the Cancer Intervention and Surveillance Modeling Network (CISNET): model D (Dana-Farber Cancer Institute) [23, 24] and model E (Erasmus MC, University Medical Center Rotterdam) [25, 26].

Model D is an analytical model that estimates breast cancer incidence and mortality as a function of disease natural history, detection process, and treatment [23, 27]. Details of IBC [24, 28] and DCIS [23, 29] modeling have been reported previously. DCIS natural history parameters were estimated using data from the Norwegian breast cancer screening program. Details of model D and estimation of model parameters can be found in Additional file 1.

Model E is a discrete event-driven micro-simulation model that simulates independent life histories of women using a parallel universe approach [25, 26]. This means that there are two identical female populations whereby one population undergoes screening and one population does not have screening. Recently, model E has been extended by including DCIS [30]. The DCIS model component is stage-specific whereby preclinical undetectable DCIS can be allowed to enter a regression state or progress to preclinical screen-detectable DCIS, clinical DCIS, or preclinical IBC. The natural history parameters for DCIS were estimated through calibration with DCIS SEER data. A more extensive description of model E can be found in Additional file 2.

Both models have been extensively evaluated on US breast cancer incidence and mortality trends [31–33] and used to estimate benefits and harms of mammography screening [34]. Both models have been used to inform breast cancer screening recommendations, for instance, by the US Preventive Services Task Force (USPSTF) [35]. A more detailed description of models D and E can be found on [https://resources.cisnet.cancer.gov/registry/packages/filter/Breast/](https://resources.cisnet.cancer.gov/registry/packages/filter/Breast/), in the Additional files and elsewhere [23, 34].

**Submodels**

In total, 6 parallel submodels were developed (represented in Fig. 1), each with its own assumptions common for both model D and model E. This includes three different proportions of DCIS lesions in the preclinical undetectable DCIS state progressing to preclinical screen-detectable DCIS (i.e., 30%, 50%, and 80%), and the ability of DCIS to regress [23, 25]. The structure of the DCIS components in models D and E is similar as they both assume that normal breast tissue can progress to preclinical DCIS which is undetectable as depicted in Fig. 1. From there onwards, preclinical undetectable DCIS can become screen-detectable or evolve into preclinical IBC. Screen-detectable DCIS can progress to preclinical IBC (P1) or clinical DCIS (P2), whereas preclinical IBC can develop into clinical IBC possibly.
leading to breast cancer death. The death state unrelated to breast cancer can result from any non-breast cancer death state in Fig. 1.

**Input parameters**

Estimated from Breast Cancer Surveillance Consortium (BCSC) data, mammography sensitivity for detecting DCIS were set to 0.45, 0.55, 0.70, and 0.85 for the periods 1975–1984, 1985–1999, 2000–2009, and 2010 onwards, respectively [24]. This reflects the improvement in mammography sensitivity over time in the USA [36]. Furthermore, both models used screening dissemination patterns in the USA over time until 2010 and extrapolated patterns thereafter [37]. Other common input parameters, such as birth tables, life tables, and age-period-cohort estimates of breast cancer incidence in the

| Submodel | Transition % from preclinical undetectable DCIS to preclinical screendetecatable DCIS | DCIS regression |
|-----------|---------------------------------------------------------------------------------|-----------------|
| 1a        | 30%                                                                             | No DCIS regression |
| 1b        | 30%                                                                             | With DCIS regression |
| 2a        | 50%                                                                             | No DCIS regression |
| 2b        | 50%                                                                             | With DCIS regression |
| 3a        | 80%                                                                             | No DCIS regression |
| 3b        | 80%                                                                             | With DCIS regression |
absence of screening, are described in a previous publication [37].

Model outcomes
The models estimated rates of overdiagnosis of DCIS and IBC (per 100,000 women) and MSTs in the screen-detectable preclinical DCIS state. DCIS overdiagnosis was defined as a screen-detected DCIS case that would not have been found in the absence of screening as it would not have progressed to clinical DCIS or clinical IBC in the remaining lifetime of the woman. Similarly, overdiagnosed IBC was defined as a screen-detected IBC case that would not have been found in the absence of screening as it would not have developed into clinical IBC in the remaining lifetime of the woman.

We also calculated overdiagnosis for DCIS, IBC, and DCIS and IBC combined by dividing the number of overdiagnosed cases by the total number of screen-detected and clinically detected cases. The MST was defined as the number of years in which DCIS is screen-detectable before it progresses to another state, which could be the preclinical IBC state, clinical DCIS state, or normal tissue (DCIS regression). For model D, the MST was an input parameter (Additional file 1) while it was an output for model E.

Statistical analysis
We generated age-specific and age-adjusted (between ages 30 and 79 years) data for birth cohorts born between 1890 and 1996. The projected age-adjusted incidence for DCIS and IBC were compared with SEER data. A chi-square test was performed to assess the goodness of fit between the projected incidence estimates and observed data of DCIS and IBC for the calendar year 1975 to 2015.

Results
Comparing SEER data and projected incidence for DCIS and IBC
Model D projected DCIS incidence that matched the SEER data relatively well for all submodels as indicated by the goodness-of-fit measures (Table 1). The model fit was better for earlier calendar years (Fig. 2). Model D showed higher DCIS incidence in later years when regression was allowed compared to no regression, except for submodel 3 where the incidence was similar regardless of DCIS regression. Model E also generated DCIS incidence that matched the SEER data relatively well as shown in Table 1, except for submodel 1b. The best fit for model E was submodels 2a and 2b where 50% of the DCIS lesions in the preclinical undetectable DCIS state progress to preclinical screen-detectable DCIS state. Model E had lower DCIS incidences when regression was allowed in submodels 2 and 3 but not 1. IBC incidence projected from both models D and E matched the SEER data relatively well for all submodels (Fig. 3).

Mean sojourn times
Models D and E estimated that the MSTs of screen-detectable preclinical DCIS lesions ranged 0.2–7.7 years, but mostly less than 4 years for the different submodels (Table 1). MST estimates varied by submodels and by DCIS progression path (i.e., progress to preclinical IBC, clinical DCIS, or regress). Model D’s estimates showed a trend towards a shorter or equal MSTs in submodel 3 (versus submodels 2 and 1). This trend was not obvious in model E. The MSTs of the lesions that progressed to preclinical IBC were shorter when DCIS regression was allowed. This trend was also seen for the lesions that will progress to clinical DCIS in all submodels for model E and in submodel 1 for model D. The MSTs of the lesions that regressed were 1.5 years in all submodels of model D and varied between 0.6 and 4.0 years in model E.

Proportion of DCIS cases progressing to other states
Figure 4 displays estimated proportions of DCIS lesions in the preclinical DCIS state that progress to other states by age for the 1930 birth cohort in the absence of screening, biopsy, and surgical excision. Assuming no DCIS regression, most submodels showed a large proportion of DCIS progressing to preclinical IBC, ranging from 64 to 100%. For submodels that allowed DCIS regression, this proportion ranged from 36 to 100%. Throughout all submodels, the proportion progressing to clinical DCIS varied from 0 to 36%. In submodels where DCIS regression was allowed, the proportion of DCIS regression was higher than the proportion progressing to clinical DCIS. Furthermore, Fig. 4 shows that younger women have a larger proportion progressing preclinical IBC compared to older women. Similar proportions of DCIS progression and age-specific trends were observed in all other birth cohorts.

Overdiagnosis of DCIS and IBC
In both models, the level of DCIS overdiagnosis increased as a function of age and calendar year as mammogram use was more widely disseminated. Both models found a higher overdiagnosis rate when DCIS regression was assumed. For example, model D estimated DCIS overdiagnosis to be 3.1–4.8% across submodels without DCIS regression; overdiagnosis increased to 13.3–19.3% when regression was allowed (Table 1). Model E had a similar trend, although the level of DCIS overdiagnosis was higher (35 to 66%). Combining DCIS and IBC, the level of overdiagnosis varied between 2.5 and 10.5%. Furthermore, both models estimated that IBC overdiagnosis increased with age (see Fig. 5).
As the natural history of DCIS is mostly unknown, it is challenging to pinpoint a unique DCIS model. This study investigated different DCIS natural history models and selected six plausible models that could explain DCIS and IBC incidence in the USA. Unlike other attempts to model the natural history of DCIS [18, 19, 38], our extensive work involved two-established modeling groups, several submodels, multiple birth cohorts, and a 40-year time span with the mammogram dissemination patterns observed in the USA [39]. Our modeling work also showed that several different natural history models fit the observed trends, making any firm conclusions about the DCIS natural history based on observation data difficult. Most submodels in our study indicated that the majority of unexcised screen-detectable preclinical DCIS lesions progress to IBC. This agrees with previous modeling studies that have estimated progression varying from 61–91% [13, 14, 17, 18]. Notably, results from our submodels showed that younger women may have a higher proportion of progression from unexcised screen-detectable DCIS to preclinical IBC. A possible explanation is that young women tend to have a more aggressive type of DCIS which is more likely to progress to IBC [3]. For women older than 50 years, our study found that the proportion of screen-detectable DCIS progressing to preclinical IBC to be between 36 and 99%. Furthermore, our study showed that the proportion of screen-detectable DCIS that could regress varied between 0 and 56%. These results are consistent with previous modeling studies that have estimated the proportion of DCIS regression was between 1 and 37% [13, 14, 40].

Observational studies of women who did not receive definitive surgery after diagnosis with DCIS have found lower rates of progression invasive cancer, ranging from 12 to 54% [4, 6–12]. However, these studies are not directly comparable to modeling results because they do not capture non-screen detected preclinical DCIS. Indeed, only modeling studies can capture progression rates of lesions uninterrupted by biopsy or other treatment. Lower progression rates in observational studies could be due to a number of factors. First, there is a chance of complete removal of the DCIS lesion during biopsy. This disruption of natural history will bias estimates, resulting in a lower estimated proportion of DCIS progressing to IBC and a non-observed sojourn time. In addition, mammography-detected lesions usually contain calcifications, and it remains unclear whether DCIS with and without calcification have the same natural history. Finally, inflammation of the stroma caused by the biopsy might alter the natural course of DCIS [41].

Table 1 Outcomes for three DCIS submodels with and without regression during 1975–2015 for women aged 30–79 years

| Goodness-of-fit Deviance (observed-estimated)^2 | Df | 1a noReg | 1b wReg | 2a noReg | 2b wReg | 3a noReg | 3b wReg |
|-----------------------------------------------|----|----------|---------|----------|---------|----------|---------|
| DCIS deviance (p value*)                      | Model D | 40 | 665 (0.98) | 1182 (0.82) | 1242 (0.79) | 2168 (0.15) | 1307 (0.77) | 1121 (0.89) |
|                                              | Model E | 40 | 1505 (0.18) | 2071 (0.004) | 698 (0.95) | 926 (0.81) | 1637 (0.12) | 1064 (0.56) |
| IBC deviance (p value*)                       | Model D | 40 | 2734 (1.00) | 2499 (1.00) | 3406 (1.00) | 2585 (1.00) | 3116 (1.00) | 3527 (1.00) |
|                                              | Model E | 40 | 3183 (1.00) | 4386 (0.98) | 6071 (0.86) | 5388 (0.95) | 5921 (0.80) | 2510 (1.00) |

Mean sojourn time

| MST of preclinical screen-detectable DCIS before progressing to preclinical IBC |
|---------------------------------|-----------------|-----------------|-----------------|
| Model D | 2.5 | 1.5 | 0.7 | 0.5 | 0.4 | 0.2 |
| Model E | 0.9 | 0.5 | 0.8 | 0.4 | 1.0 | 0.6 |

| MST of preclinical screen-detectable DCIS before progressing to clinical DCIS |
|---------------------------------|-----------------|-----------------|-----------------|
| Model D | 2.5 | 1.5 | 1.9 | 1.9 | 1.9 | 1.9 |
| Model E | 3.9 | 3.1 | 4.5 | 0.9 | 7.7 | 1.4 |

| MST of preclinical screen-detectable DCIS before regressing |
|---------------------------------|-----------------|-----------------|-----------------|
| Model D | NA | 1.5 | NA | 1.5 | NA | 1.5 |
| Model E | NA | 4.0 | NA | 1.3 | NA | 0.6 |

Overdiagnosis

| % DCIS overdiagnosis | Model D | 4.8% | 19.3% | 3.4% | 13.3% | 3.1% | 19.1% |
|                      | Model E | 35.2% | 65.8% | 33.7% | 62.2% | 33.6% | 47.8% |

| % IBC overdiagnosis | Model D | 2.4% | 2.4% | 2.4% | 2.4% | 2.4% | 2.4% |
|                     | Model E | 1.4% | 1.4% | 1.4% | 1.4% | 1.3% | 1.4% |

| % DCIS + IBC overdiagnosis | Model D | 2.7% | 5.1% | 2.5% | 4.2% | 2.5% | 5.0% |
|                           | Model E | 6.0% | 10.5% | 5.8% | 9.7% | 6.7% | 8.6% |

DCIS ductal carcinoma in situ, IBC invasive breast cancer, NA not available, Df degree of freedom, noReg model without DCIS regression, wReg model with DCIS regression
*p values from chi-square tests; mean sojourn times are expressed in number of years
Fig. 2 DCIS incidence and overdiagnosis. Each graph includes SEER data and 2 submodels (1 without DCIS regression and 1 with DCIS regression). The projections include women in the age group 30–79 years. noReg, model without DCIS regression; wReg, model with DCIS regression; OD, overdiagnosis.
Fig. 3 IBC incidence and overdiagnosis. Each graph includes SEER data and 2 submodels (1 without DCIS regression and 1 with DCIS regression). The projections include women in the age group 30–79 years. noReg, model without DCIS regression; wReg, model with DCIS regression; OD, overdiagnosis.
**Fig. 4** Proportion of DCIS cases progressing to other states. Stacked bar plots showing the proportion of preclinical screen-detectable DCIS progressing to preclinical invasive breast cancer (P1), clinical DCIS (P2), or no breast cancer (P3; regression). P1, P2, and P3 are represented by blue, red, and green bars, respectively. Simulated birth cohort 1930.
An interesting finding from our study was that across all submodels the MSTs were relatively short, in particular when assuming DCIS regression. This agrees with previous modeling studies estimating MSTs between 0.5 months to 2.6 years under the assumption that IBC progresses through screen-detectable DCIS [13, 17–19]. Although our results show a similar direction as previous studies, all DCIS modeling studies are subject to overdiagnosis by age. Calendar year 2010. Each graph includes overdiagnosis for DCIS and IBC. DCIS, ductal carcinoma in situ; IBC, invasive breast cancer; noReg, submodel without DCIS regression; wReg, with DCIS regression.
considerable residual uncertainty of the estimates. Nevertheless, short MSTs for preclinical screen-detectable DCIS progressing to clinical DCIS and IBC could guide discussions on screening intervals in proposing screening guidelines. With regard to treatment, it remains difficult to make suggestive recommendations about treatment for DCIS patients unless a clinical factor and/or molecular signatures can be identified, providing insight into which women can avoid or postpone treatment [42].

The level of overdiagnosis of breast cancer is challenging to quantify, especially for screen-detected DCIS. Overdiagnosis estimates for DCIS varied between models D and E, with model D showing consistently lower level of DCIS overdiagnosis compared to model E and previous studies [13, 19, 43]. This difference is probably due to model D having shorter estimated MSTs in preclinical DCIS, and high progression rates to IBC, leading to lower DCIS overdiagnosis estimates. In contrast to model D where the sojourn time is used as an input, model E estimates the mean sojourn times for every submodel. Model D used the Norwegian breast cancer screening data to estimate the DCIS model parameters, while model E was developed on US data only.

Our study showed that DCIS overdiagnosis varied from 13 to 66% when DCIS regression was allowed and 3 to 35% when assuming no DCIS regression. Yen et al. [13] also estimated that the proportion of the screen-detected DCIS that is non-progressive (not progressing to IBC) varies from 19 to 46% in the prevalence screen and from 3 to 21% in the first subsequent screen. Another study by Seigneurin et al. estimated that 20.3% (95% CI, 3.0–38.9%) of in situ cancer was overdiagnosed, assuming that non-progressive in situ cancer remains in the preclinical phase [44]. With regard to IBC in our study, overdiagnosis was on average between 1.3 and 2.4% regardless of the assumptions of DCIS regression for the age group 30–79 years. This falls in the range of 1–10% for overdianosed IBC reported in the systematic review conducted by Puliti et al. based on European studies [45]. Despite the variation in estimated DCIS overdiagnosis levels by submodel, the overall level of overdiagnosis of DCIS+IBC was not high, ranging 2.5–10.5%.

Most submodels in this study showed a reasonable fit with SEER data, indicating that different sets of parameters can match observed breast cancer rates. The ability to fit population data with varied parameters highlights the difficulty in providing definitive conclusions on the natural history of DCIS. This difficulty makes the pending results of the currently enrolling active monitoring trials LORD, LORIS, and COMET even more critical [20–22]. Although these trials focus on the disease progression of screen-detected, biopsied low-risk lesions, they will significantly enhance our understanding of overall clinical management of DCIS. Further research should focus on the heterogeneity of DCIS in various age groups as younger women may tend to have a more aggressive type of DCIS. Also, future modeling work by DCIS grade, molecular subtype, and inherent factors such as family history of breast cancer will provide more specific information on MSTs and progression of the disease that will contribute to guiding women with specific features on screening and treatment.

**Conclusion**

Our study suggested that the majority of unexcised screen-detecable preclinical DCIS lesions progress to IBC and that the MSTs are relatively short. Furthermore, our modeling work also showed that several different natural history models fit the observed trends, making any firm conclusions about the DCIS natural history based on observation data difficult. Due to the heterogeneity of DCIS, more research is needed to understand the progression of DCIS by grades, molecular subtypes, and certain inherent factors such as family history of breast cancer.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s13058-020-01287-6.

**Additional file 1.** Model D description.

**Additional file 2.** Model E description.

**Abbreviations**

DCIS: Ductal carcinoma in situ; IBC: Invasive breast cancer; MST: Mean sojourn time; SEER: Surveillance, Epidemiology and End Results; CISNET: Cancer Intervention and Surveillance Modeling Network; Model D: Model developed by Dana-Farber Cancer Institute; Model E: Model developed by Erasmus MC, University Medical Center Rotterdam; USPSTF: United States Preventive Services Task Force; BCSC: Breast Cancer Surveillance Consortium

**Acknowledgements**

We thank Dr. Amy Trentham-Dietz (University of Wisconsin-Madison) for providing us support and helpful comments on an earlier version of this manuscript.

**Authors’ contributions**

SC drafted the manuscript, and all authors contributed to review and revision. SC, NTvR, XL, HH, HJdK, and SJL designed the study. SC, NTvR, XL, HH, and SJL analyzed the data and produced all figures and tables. All authors have seen and approved the final version. All authors proofread the manuscript and were involved in editing.

**Funding**

This work was supported by the National Institutes of Health under National Cancer Institute (1U01CA199218, R01CA164301). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, Netherlands. 2Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. 3Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 4Oslo Center for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway. 5Department of Population Health Sciences, Duke University Medical Center, Durham, NC, USA. 6Department of Mathematics, Duke University, Durham, NC, USA. 7Department of Pathology and Laboratory Medicine, Lerner College of Medicine, University of Vermont and UVM Cancer Center, Burlington, VT, USA. 8Radiology Department, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 9Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

Received: 21 October 2019 Accepted: 3 May 2020
Published online: 27 May 2020

References
1. Oseni TO, Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg. 2019;228(6):952–9.
2. Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res. 2006;8(2):204.
3. Maxwell AJ, Clements MK, Hilton MB, Dodwell DJ, Evans A, Kearins MO, et al. Risk factors for the development of invasive cancer in unexcised ductal carcinoma in situ. Eur J Surg Oncol. 2018;44(4):249–35.
4. Eribs B, Provenzano E, Armes J, Gentic D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44.
5. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002;52(5):256–76.
6. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49(4):751–8.
7. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4.
8. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms the need for local recurrence even after more than 30 years of follow-up. Cancer. 2005;103(25):6113–24.
9. Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46(54):919–25.
10. Collins LC, Tamimi RM, Baer HI, Connolly IL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005;103(9):1778–84.
11. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11(3):223–35.
12. Ryser MD, Weaver DL, Zhao F, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019;111(9):952–60.
13. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003;39(12):1746–54.
14. Seigerman A, François O, Labarère J, Oudéville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011;343:d7017.
15. de Koning HJ, Draisma G, Fracheboud J, de Bruin A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res. 2005;8(8):12202.
16. Ryser MD, Worri M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst. 2015;108(5):djv372.
17. De Gelder R, Heijnsdijk EA, Van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33(1):111–21.
18. Tan KH, Simonella L, Hee RL, Roellin A, Lim YM, Lim WY, et al. Quantifying the natural history of breast cancer. Br J Cancer. 2013;109(8):2035.
19. Gunstey NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res. 2012;14(6):R152.
20. Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol. 2015;27(1):6–8.
21. Elshof LE, Tryfonidis K, Slabber L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORIS study. Eur J Cancer. 2015;51(12):1497–510.
22. Youngworth LM, Boughhey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET trial. Bull Am Coll Surg. 2017;102(6):3–35.
23. Lee SJ, Li X, Huang H, Zelen M. The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: an Update. Med Decis Making. 2018;38(1):545S–655S.
24. Lee S, Zelen M. Chapter 11: a stochastic model for predicting the mortality of breast cancer. JNCI Monographs. 2006;2006(36):79–86.
25. van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Med Decis Making. 2018;38(1_suppl):545S–655S.
26. Tan SYGL, Van Oortmanssen GJ, De Koning HJ, Boer R, Habberman JDF. Chapter 9: the MISCAN-Fadia continuous tumor growth model for breast cancer. JNCI Monographs. 2006;2006(36):56–65.
27. Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. JASA. 1998;93(440):1271–81.
28. Lee SJ, Zelen M. Mortality modeling of early detection programs. Biometrics. 2006;62(2):386–95.
29. Xi X, Weedon-Faker H, Lee SJ, Evaluating the natural history of ductal carcinoma in situ breast cancer using Norwegian breast cancer screening program data. Stat Methods Med Res. 2018;in press.
30. van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia: an overview of CISNET model approaches. Med Decis Making. 2018;38(1_suppl):1265–395.
31. Munoz D, rear, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11):2283–94.
32. Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Rear AM, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319(2):154–64.
33. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.
34. Mandelblatt JS, Stout NK, Schechter CB, Van Den Broek JJ, Miglioretti DL, Kapcho M, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4):215–25.
35. Mandelblatt JS, Cronin K, de Koning H, Miglioretti DL, Schechter CS, Stout N. Model Evaluation Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. AHRQ Publication No. 14-05201-EF-4. Rockville, MD: U.S. Preventive Services Task Force; 2015.
36. Ichikawa LE, Barlow WE, Anderson ML, Taplin SH, Geller BM, Brenner RJ. Time trends in radiologists’ interpretive performance at screening mammography from the community-based Breast Cancer Surveillance Consortium, 1996–2004. Radiology. 2010;256(1):74–82.
38. Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, et al. Common model inputs used in CISNET collaborative breast cancer modeling. Med Decis Making. 2018;38(1_suppl):95–235.
39. Ozmene EM, Shieh Y, Bames J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011;129(1):165–73.
39. Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16(6):701–12.

40. Van Luijt PA, Heijnsdijk EAM, Fracheboud J, Overbeek LIH, Broeders MJM, Wesseling J, et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4252 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. 2016;18(1):47.

41. Szalayova G, Ogrodnik A, Spencer B, Wade J, Bunn J, Ambaye A, et al. Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat. 2016;157(3):461–74.

42. Doke K, Butler S, Mitchell MP. Current therapeutic approaches to DCIS. J Mammary Gland Biol Neoplasia. 2018;23(4):279–91.

43. Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol. 2016;17(1):109–14.

44. Seigneurin A, Labarère J, François O, Exbrayat C, Dupouy M, Filippi M, et al. Overdiagnosis and overtreatment associated with breast cancer mammography screening: a simulation study with calibration to population-based data. Breast. 2016;28:60–6.

45. Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19(1_suppl):42–56.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.